All In Biotech

Drug Trial Radar · NCT06407934

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 52-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,541 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,541

Actual

Start

May 8, 2024

Primary completion

Jun 10, 2026

Study completion Mar 17, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The primary objective of ESTUARY is to assess the maintenance of treatment response on continued Q12W dosing compared to treatment withdrawal. Study details include: The study duration will be up to 68 weeks including a 52-week randomized double-blind period, and a 16-week safety follow-up for participants not entering the LTS17367 (RIVER-AD). The study duration will be up to 52 weeks for participants entering the LTS17367 \[RIVER-AD\] study at the Week 52 visit of EFC17600 (ESTUARY).

Conditions

  • Dermatitis Atopic

Interventions

  • AmlitelimabDrug

    Pharmaceutical form: Injection solution Route of administration: Subcutaneous (SC) injection

  • PlaceboDrug

    Pharmaceutical form: Injection solution Route of administration: SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. US and US reference countries: Proportion of participants who are responders AND maintained vIGA-AD ≤2 without experiencing relapse among participants who were responders at baseline of ESTUARYTime frame: Week 24
  2. EU, EU Reference Countries, and Japan: Proportion of participants who maintain treatment response in ESTUARY without experiencing relapseTime frame: Week 48

Locations

324 sites in 27 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center- Site Number : 8401066

    Birmingham, Alabama

  • Center for Dermatology and Plastic Surgery- Site Number : 8401119

    Scottsdale, Arizona

  • Scottsdale Clinical Trials- Site Number : 8401149

    Scottsdale, Arizona

  • Eclipse Clinical Research- Site Number : 8401158

    Tucson, Arizona

  • Johnson Dermatology- Site Number : 8401076

    Fort Smith, Arkansas

  • Encino Research Center- Site Number : 8401042

    Encino, California

  • First OC Dermatology- Site Number : 8401025

    Fountain Valley, California

  • Center for Dermatology Clinical Research- Site Number : 8401018

    Fremont, California

  • Marvel Clinical Research- Site Number : 8401102

    Huntington Beach, California

  • Sunwise Clinical Research- Site Number : 8401022

    Lafayette, California

  • Torrance Clinical Research - Narbonne Avenue- Site Number : 8401027

    Lomita, California

  • Dermatology Research Associates - Los Angeles- Site Number : 8401092

    Los Angeles, California

  • LA Universal Research Center- Site Number : 8401064

    Los Angeles, California

  • Northridge Clinical Trials - Northridge- Site Number : 8401080

    Northridge, California

  • Cura Clinical Research - Oxnard- Site Number : 8401142

    Oxnard, California

  • Southern California Dermatology- Site Number : 8401043

    Santa Ana, California

  • Clinical Science Institute- Site Number : 8401028

    Santa Monica, California

  • UConn Health - Farmington- Site Number : 8401115

    Farmington, Connecticut

  • Pediatric Skin Research- Site Number : 8401198

    Coral Gables, Florida

  • St. Jude Clinical Research- Site Number : 8401287

    Doral, Florida

  • Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286

    Fort Myers, Florida

  • Direct Helpers Research Center- Site Number : 8401056

    Hialeah, Florida

  • Encore Medical Research - Hollywood- Site Number : 8401030

    Hollywood, Florida

  • Clever Medical Research- Site Number : 8401160

    Miami, Florida

  • Acevedo Clinical Research Associates- Site Number : 8401088

    Miami, Florida

  • Florida International Research Center- Site Number : 8401091

    Miami, Florida

  • Miami Dermatology and Laser Research - Miami - Southwest 87th Avenue- Site Number : 8401086

    Miami, Florida

  • Anchor Medical Research- Site Number : 8401300

    Miami, Florida

  • Savin Medical Group - Miami Lakes- Site Number : 8401085

    Miami Lakes, Florida

  • Nuline Clinical Trial Center- Site Number : 8401161

    Pompano Beach, Florida

  • Global Clinical Professionals (GCP)- Site Number : 8401045

    St. Petersburg, Florida

  • Clinical Research Trials of Florida- Site Number : 8401023

    Tampa, Florida

  • AllerVie Clinical Research - Columbus- Site Number : 8401104

    Columbus, Georgia

  • Cleaver Medical Group- Site Number : 8401138

    Dawsonville, Georgia

  • First Georgia Physician Group- Site Number : 8401190

    Fayetteville, Georgia

  • Skin Care Physicians of Georgia - Macon- Site Number : 8401034

    Macon, Georgia

  • Javara Research - Thomasville- Site Number : 8401189

    Thomasville, Georgia

  • Rophe Adult & Pediatric Medicine- Site Number : 8401289

    Union City, Georgia

  • NorthShore University Health System - Endeavor Health Medical Group - Skokie - Woods Drive- Site Number : 8401038

    Skokie, Illinois

  • Dawes Fretzin Clinical Research- Site Number : 8401015

    Indianapolis, Indiana

Showing 40 of 324 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.